Efficacy and safety of danuglipron ( Diabetes Obesity Metab
Protective effect of L-carnitine on hyperammonemia [PMID: 6692930] Laboratory literature summary: Protective effect of L-carnitine on hyperammonemia
10.2337/db10-1740 5 BahneE.SunE
According to the FDA prescribing information, gastrointestinal adverse reactions are very common, with nausea (24-37%), diarrhea (18-26%), vomiting (8-25%), and constipation (16-24%) occurring frequently across clinical trials
Fasting While on Tirzepatide: Safety Considerations Intermittent fasting (IF) during tirzepatide therapy is possible for many patients but requires attention to hydration, electrolyte balance, and nutrient timing
However, 85% of those who continue treatment past week 4 report significant improvement in side effects